Feature article - A CDMO’s insight into the M&A landscape
Mark Quick, EVP of corporate development at Recipharm, discusses the M&A trend within the CDMO industry
M&A activity within the pharmaceutical industry remains at a high. According to Ernst & Young (EY), M&A strategies have increased by around 12% year-on-year since 2012.1 CDMOs are some of the major players in these high-value deals, seeing it as a valuable strategy that enables to capitalise on another company’s strengths and thus better position their organisations to meet market demands and realise a more competitive edge.
